Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer With Durable Disease Control: A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of Life

NCT06207734 is registered in ClinicalTrials.gov with Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest as lead sponsor.

NCT NCT06207734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06207734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer With Durable Disease Control: A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of Life
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase
Phase 2
Overall status
Recruiting
Start date
January 17, 2024
Completion date
July 10, 2028
Enrollment
120 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer